L Number	Hits	Search Text	DB	Time stamp
1	387	536/17.4	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 09:55
2	4	536/17.4 and azetidinone	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 09:56
3	2381	514/23	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 09:56
4	9	514/23 and azetidinone	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 10:02
5	133	514/210.02	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 10:03
6	62	514/210.02 and azetidinone	USPAT; US-PGPUB; EPO; DERWENT	2003/09/07 10:03

(Untitled)





chain nodes :
5 18 19 20 22
ring nodes :
1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 21 23 24 25 26 27
chain bonds :
1-12 2-5 3-18 4-6 18-19 19-20 20-21 20-22
ring bonds :
1-2 1-4 2-3 3-4 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16
16-17 21-23 21-27 23-24 24-25 25-26 26-27
exact/norm bonds :
1-2 1-4 1-12 2-3 2-5 3-4 20-22
exact bonds :
3-18 4-6 18-19 19-20 20-21
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 21-23 21-27
23-24 24-25 25-26 26-27

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS
21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	AUG 22	Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation

```
 NEWS 38  AUG 18  Simultaneous left and right truncation added to ANABSTR

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:50:17 ON 07 SEP 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 07 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     5 SEP 2003  HIGHEST RN 580198-40-9
DICTIONARY FILE UPDATES:    5 SEP 2003  HIGHEST RN 580198-40-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10021502-1.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 10:50:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 173 TO 747
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN D-glycero-D-gulo-Heptitol, 2,6-anhydro-1-O-[3-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl]-2-propenyl]- (9CI)
MF C34 H37 F2 N O8

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-[4-[3-[[6-[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)carbonyl]amino]-1-oxohexyl]amino]-1-propynyl]phenyl]-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI)
MF C60 H54 F N3 O16

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
FULL SEARCH INITIATED 10:51:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 488 TO ITERATE

100.0% PROCESSED 488 ITERATIONS 218 ANSWERS
SEARCH TIME: 00.00.01

L3 218 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.95	149.16

FILE 'CAPLUS' ENTERED AT 10:52:15 ON 07 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Sep 2003 VOL 139 ISS 11
FILE LAST UPDATED: 5 Sep 2003 (20030905/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3 and composition
           110 L3
        606547 COMPOSITION
        263931 COMPOSITIONS
        865452 COMPOSITION
                 (COMPOSITION OR COMPOSITIONS)
       1242948 COMPN
        494645 COMPNS
       1519862 COMPN
                 (COMPN OR COMPNS)
       1951035 COMPOSITION
                 (COMPOSITION OR COMPN)
L4          16 L3 AND COMPOSITION

=> s l4 and (antidiabetic or HMG or PPAR)
         12384 ANTIDIABETIC
          4862 ANTIDIABETICS
         14982 ANTIDIABETIC
                 (ANTIDIABETIC OR ANTIDIABETICS)
          7950 HMG
            93 HMGS
          7970 HMG
                 (HMG OR HMGS)
          3697 PPAR
           534 PPARS
          3762 PPAR
                 (PPAR OR PPARS)
L5           9 L4 AND (ANTIDIABETIC OR HMG OR PPAR)

=> dis l4 1-16 bib abs hitstr

L4   ANSWER 1 OF 16  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:633275  CAPLUS
DN   139:169333
TI   Novel anticholesterol compositions and method for using same
IN   Dudley, Robert; Liao, Shutsung; Song, Ching
PA   USA
SO   U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 8
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   US 2003153541      A1   20030814       US 2002-174934   20020619
     WO 9922728         A1   19990514       WO 1998-US23041  19981030
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6576660         B1   20030610       US 2000-530443   20000428
     US 2002107233      A1   20020808       US 2002-72128    20020208
     US 2002193357      A1   20021219       US 2002-137695   20020502
PRAI US 1997-63770P     P    19971031
     WO 1998-US23041    W    19981030
     US 1999-131728P    P    19990430
     US 2000-530443     A2   20000428
     US 2000-560236     A2   20000428
     US 2001-267493P    P    20010208
     US 2001-288643P    P    20010503
```

US 2001-348020P P 20011108
US 2002-72128 A2 20020208
US 2002-137695 A2 20020502

AB Disclosed are **compns**., methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concn., for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The **compns**., methods, combinations, and kits of the present invention are pharmaceutical **compns**. comprising at least two of an LXR receptor modulator, a therapeutically effective amt. of a catechin, and/or a therapeutically effective amt. of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid deriv., niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3 fatty acid.

IT **163222-33-1**, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholesterol **compns**. contg. LXR modulators and lipid regulating agents)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:511859 CAPLUS
DN 139:90459
TI Use of an immediate-release powder in pharmaceutical and nutraceutical **compositions**
IN Besse, Jerome; Besse, Laurence
PA Fr.
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003124191	A1	20030703	US 2002-106923	20020325
	FR 2834212	A1	20030704	FR 2001-16934	20011227
	WO 2003055464	A1	20030710	WO 2002-FR4575	20021227

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI FR 2001-16934 A 20011227

AB The present invention relates to the use of a powder comprising at least one active substance, at least one surfactant, at least one wetting agent and at least one diluent, for prepg. a pharmaceutical or nutraceutical **compn.**, this **compn.** allowing rapid and immediate release of the active substance. Granules contg. phloroglucinol 10, sorbitol 89, and propylene glycol 1% were prepd.

IT **163222-33-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of immediate-release powder in pharmaceutical and nutraceutical **compns.**)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:492702 CAPLUS

DN 139:47580

TI Combinations of hormone replacement therapy **composition**(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women

IN Strony, John T.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003119796	A1	20030626	US 2002-247085	20020919
	US 2003105028	A1	20030605	US 2002-166942	20020611
PRAI	US 2001-324118P	P	20010921		
	US 2002-166942	A2	20020611		
	US 2000-256875P	P	20001220		
	US 2001-23295	A2	20011217		

OS MARPAT 139:47580

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one hormone replacement therapy **compn.**; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5.alpha.-stanols.

IT **163222-32-0P 163222-33-1P 163380-15-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of sterol absorption inhibitors for the combined use with hormone replacement therapy **compns**. and treatments for vascular conditions in post-menopausal women)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 163380-15-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:492667 CAPLUS
DN 139:57965
TI Methods and therapeutic combinations for the treatment of obesity using

sterol absorption inhibitors
IN Davis, Harry R.; Ress, Rudyard J.; Strony, John T.; Veltri, Enrico P.
PA Schering Corporation, USA
SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003119428	A1	20030626	US 2002-247397	20020919
	US 2003105028	A1	20030605	US 2002-166942	20020611
PRAI	US 2001-323840P	P	20010921		
	US 2002-166942	A2	20020611		
	US 2000-256875P	P	20001220		
	US 2001-23295	A2	20011217		

OS MARPAT 139:57965
AB The present invention provides methods for the treatment of obesity using sterol or 5.alpha.-stanol absorption inhibitors and **compns**. and therapeutic combinations including sterol or 5.alpha.-stanol absorption inhibitors and at least one obesity control medication. Prepn. of azetidinone derivs. is described. A tablet contained active compd. 102, lactose monohydrate 553, microcryst. cellulose 204, povidone (K29-32) 45, croscarmellose sodium 86, sodium lauryl sulfate 27, and magnesium stearate 1 mg.
IT **163222-33-1P 163380-16-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods and therapeutic combinations for treatment of obesity using sterol absorption inhibitors)
RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 163380-16-3 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-32-0P 163380-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods and therapeutic combinations for treatment of obesity using sterol absorption inhibitors)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163380-15-2 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:435299 CAPLUS

DN 139:22062

TI Preparation of substituted 2-azetidinones and use as hypocholesterolemic agents

IN Ghosal, Anima; Zbaida, Shmuel; Chowdhury, Swapan K.; Iannucci, Robert M.; Feng, Wenqing; Alton, Kevin B.; Patrick, James E.; Davis, Harry R.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 23,295.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003105028	A1	20030605	US 2002-166942	20020611
	US 2002137690	A1	20020926	US 2001-23295	20011217
	US 2003119757	A1	20030626	US 2002-247032	20020919
	US 2003119796	A1	20030626	US 2002-247085	20020919
	US 2003119428	A1	20030626	US 2002-247397	20020919
PRAI	US 2000-256875P	P	20001220		
	US 2001-23295	A2	20011217		
	US 2001-323840P	P	20010921		
	US 2001-323937P	P	20010921		
	US 2001-324118P	P	20010921		
	US 2002-166942	A2	20020611		

OS MARPAT 139:22062
GI



I



II

AB The authors report the prepn. of substituted 2-azetidinone compds. I [R1 = H, SO3H, Q1, etc., R3, R4, R5 = H, C1-C6 alkyl, CO-aryl, etc., R6 = H, C1-C6 alkyl, COMe, etc., R8 = H, alkyl, R26 = H, OH, F, etc., Ar1 = aryl, heteroaryl, etc., Ar2 = aryl, heteroaryl, etc., L = covalent bond, CO, phenylene, etc., Q = (CH2)n, n = 2-6, spiro group, etc.], as well as methods of lowering cholesterol by administering said compds., pharmaceutical **compns**. contg. them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis. Thus, 14C-Sch 58235 was converted to the benzylic glucuronide II using UDPGA (uridine diphosphoglucuronosyltransferase) as catalyst.

IT **163222-33-1P**, Sch 58235
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **190448-57-8**, Sch 60663

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(prepn. of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 190448-57-8 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **438576-93-3**

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azetidinone glucuronide derivs. and their use as hypocholesterolemic agents for treating diabetes, obesity, vascular conditions, and lowering plasma sterol concns.)

RN 438576-93-3 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, labeled with carbon-14, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:868252 CAPLUS
DN 138:348551
TI Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte
AU Repa, Joyce J.; Dietschy, John M.; Turley, Stephen D.
CS Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
SO Journal of Lipid Research (2002), 43(11), 1864-1874
CODEN: JLPRAW; ISSN: 0022-2275
PB Lipid Research, Inc.
DT Journal
LA English
AB Intestinal cholesterol absorption is a major determinant of plasma low d. lipoprotein-cholesterol (LDL-C) concns. Ezetimibe (SCH 58235) and its analogs SCH 48461 and SCH 58053 are novel potent inhibitors of cholesterol absorption whose mechanism of action is unknown. These studies investigated the effect of SCH 58053 on cholesterol metab. in female 129/Sv mice. In mice fed a low cholesterol rodent diet contg. SCH 58053, cholesterol absorption was reduced by 46% and fecal neutral sterol excretion was increased 67%, but biliary lipid **compn**. and bile acid synthesis, pool size, and pool **compn**. were unchanged. When the dietary cholesterol content was increased either 10- or 50-fold, those animals given SCH 58053 manifested lower hepatic and biliary cholesterol concns. than did their untreated controls. Cholesterol feeding increased the relative mRNA level for ATP-binding cassette transporter A1 (ABCA1), ABC transporter G5 (ABCG5), and ABC transporter G8 (ABCG8) in the jejunum, and of ABCG5 and ABCG8 in the liver, but the magnitude of this increase was generally less if the mice were given SCH 58053. We conclude that the inhibition of cholesterol absorption effected by this new class of agents is not mediated via changes in either the size or **compn**. of the intestinal bile acid pool, or the level of mRNA expression of proteins that facilitate cholesterol efflux from the enterocyte, but rather may involve disruption of the uptake of luminal sterol across the microvillus membrane.
IT **163222-33-1**, Ezetimibe
RL: DMA (Drug mechanism of action); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte)
RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:716094 CAPLUS
DN 137:226612
TI Antihypertensive agent and cholesterol absorption inhibitor combination therapy
IN Nichtberger, Steven A.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072104	A2	20020919	WO 2002-US6570	20020305
WO 2002072104	A3	20030724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-274288P P 20010308
AB The invention includes methods for treating atherosclerosis and preventing atherosclerotic disease events in a hypertensive patient comprising administering to the patient a therapeutically or prophylactically effective amt. of at least one antihypertensive compd. in combination with a therapeutically effective amt. of a cholesterol absorption inhibitor. The invention also includes a **compn**. comprising at least one antihypertensive compd. and a cholesterol absorption inhibitor in therapeutically effective amts., and a pharmaceutically acceptable carrier.
IT **163222-33-1**, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antihypertensive agent and cholesterol absorption inhibitor combination therapy)
RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:575765 CAPLUS
DN 137:140435
TI Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical **compositions**, and use
IN Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
PA USA
SO U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002103242	A1	20020801	US 2001-21667	20011029
	WO 2002060434	A2	20020808	WO 2001-US49501	20011026
	WO 2002060434	A3	20030619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-244698P P 20001031
OS MARPAT 137:140435
GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH2, CO; R1 = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R1 forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO2, CH2, (un)substituted NH; n = 1-6; R4 = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their prepn. is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH2O(CH2)3Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alk. hydrolysis (100%), to give title compd. II. PPAR binding assays using human recombinant PPAR are described without data. Co-administration of compds. I with a variety of other drug categories, including a no. of specific drugs, is claimed.

IT **163222-33-1**, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic **compns**. also contg.; prepn. of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574958 CAPLUS
DN 137:135087
TI Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.
PA Schering Corporation, USA
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058734	A2	20020801	WO 2002-US2013	20020125
	WO 2002058734	A3	20030703		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002147184	A1	20021010	US 2002-56680	20020125
	US 2002192203	A1	20021219	US 2002-136968	20020501
PRAI	US 2001-264275P	P	20010126		
	US 2001-264396P	P	20010126		
	US 2001-264600P	P	20010126		
	US 2001-324123P	P	20010921		
	US 2001-323839P	P	20010921		
	US 2002-57323	A3	20020125		

OS MARPAT 137:135087
AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor administered in an amt. of 0.1-1000 mg/day; and (b) at least one blood modifier administered in an amt. of 1-1000 mg/day, which can be useful for treating vascular conditions, e.g., diabetes and obesity, and lowering plasma levels of sterols in mammals. A sterol absorption inhibitor is an azetidinone compd. or a .beta.-lactam, while a blood modifier was selected from anticoagulants, antithrombotics, fibrinogen receptor antagonists, platelet aggregation inhibitors, hemorheol. agents, lipoprotein assocd. coagulation inhibitors, Factor VIIa inhibitors, and Factor Xa inhibitors. Prepn. of a sterol inhibitor ezetimibe is described.
IT **163222-32-0P 163380-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders)
RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163380-15-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-33-1P**, Ezetimibe **163380-16-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders)
RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 163380-16-3 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574957 CAPLUS
DN 137:135086
TI Combinations of bile acid sequestrant(s) and azetidinone sterol absorption inhibitor(s) and treatments for vascular indications
IN Davis, Harry R.; Kosoglou, Teddy
PA Schering Corporation, USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058733	A2	20020801	WO 2002-US2010	20020125
	WO 2002058733	C2	20021121		
	WO 2002058733	A3	20030626		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003053981	A1	20030320	US 2002-57534	20020125
PRAI	US 2001-264600P	P	20010126		
	US 2001-323842P	P	20010921		

OS MARPAT 137:135086
GI



I

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT **163222-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:574956 CAPLUS

DN 137:129904

TI Combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases

IN Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard

PA Schering Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058732	A2	20020801	WO 2002-US2009	20020125
	WO 2002058732	A3	20030703		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002151536	A1	20021017	US 2002-57323	20020125
	US 2002192203	A1	20021219	US 2002-136968	20020501
PRAI	US 2001-264396P	P	20010126		
	US 2001-323839P	P	20010921		
	US 2002-57323	A3	20020125		

OS MARPAT 137:129904

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (PPAR) activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone 4, croscarmellose sodium 8, sodium lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets contg. a PPAR activator such as ezetimibe. Synthetic prepn. of ezetimibe from fluorohenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of fenofibrate was well tolerated and caused a significant redn. in LDL-C as compared to either drug alone or placebo.

IT **163222-33-1**, Ezetimibe.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574955 CAPLUS
DN 137:129903
TI Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058731	A2	20020801	WO 2002-US1196	20020125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003069221	A1	20030410	US 2002-57339	20020125
	US 2002192203	A1	20021219	US 2002-136968	20020501
PRAI	US 2001-264275P	P	20010126		
	US 2001-264396P	P	20010126		
	US 2001-264600P	P	20010126		
	US 2001-323842P	P	20010921		
	US 2001-323839P	P	20010921		
	US 2002-57323	A3	20020125		

OS MARPAT 137:129903
GI



I

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepd. contg. cardiovascular agents which can be coadministered with formulations contg., e.g., I. The prepn. of I was given.

IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-33-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574926 CAPLUS
DN 137:135094
TI The use of substituted azetidinone compounds for the treatment of sitosterolemia
IN Davis, Harry R.
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058696	A2	20020801	WO 2002-US1195	20020125
	WO 2002058696	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2002169134	A1	20021114	US 2002-57629	20020125
PRAI	US 2001-264645P	P	20010126		

OS MARPAT 137:135094
GI



I

AB The invention discloses the use of sterol absorption-inhibiting compds., pharmaceutical **compns**. thereof, therapeutic combinations, and their use in combination with other lipid-lowering agents to treat or prevent sitosterolemia and/or to lower the concn. of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or

preventing vascular disease and coronary events also are provided. The methodol. and **compns**. of the invention use substituted azetidinone compds., e.g. I (prepn. described).

IT **163222-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(azetidinone derivs. for treatment of sitosterolemia)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **444313-49-9 444313-50-2 444313-51-3**
444313-53-5 444313-55-7 444313-57-9
444313-59-1 444313-60-4 444313-61-5
444313-62-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(azetidinone derivs. for treatment of sitosterolemia)

RN 444313-49-9 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75330-75-5
CMF C24 H36 O5

Absolute stereochemistry.



RN 444313-50-2 CAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (.beta.R,.delta.R,1S,2S,6S,8S,8aR)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 81093-37-0
CMF C23 H36 O7

Absolute stereochemistry.



RN 444313-51-3 CAPLUS
CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-rel-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 93957-54-1
CMF C24 H26 F N O4

Relative stereochemistry.
Double bond geometry as shown.



RN 444313-53-5 CAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 79902-63-9
CMF C25 H38 O5

Absolute stereochemistry.



RN 444313-55-7 CAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (.beta.R,.delta.R)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 134523-00-5
CMF C33 H35 F N2 O5

Absolute stereochemistry.



RN 444313-57-9 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



RN 444313-59-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-, mixt. with (4R,6S)-6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 141750-63-2
CMF C25 H22 F N O3

Absolute stereochemistry.
Double bond geometry as shown.



RN 444313-60-4 CAPLUS
CN Cholestyramine, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 11041-12-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 444313-61-5 CAPLUS
CN 1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 182815-44-7
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x . x Cl H

CM 3

CRN 182815-43-6
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x
CCI PMS

CM 4

CRN 182815-42-5
CMF C12 H27 N2 . Cl



CM 5

CRN 92162-19-1
CMF C13 H27 N



CM 6

CRN 107-11-9
CMF C3 H7 N



CM 7

CRN 106-89-8
CMF C3 H5 Cl O



RN 444313-62-6 CAPLUS
CN Colestipol, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 50925-79-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **163222-32-0P 163380-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; azetidinone derivs. for treatment of sitosterolemia)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163380-15-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574915 CAPLUS
DN 137:119671
TI Combinations of nicotinic acid and derivatives thereof and azetidine sterol absorption inhibitor(s) and treatments for vascular indications
IN Davis, Harry R.; Kosoglou, Teddy
PA Schering Corporation, USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058685	A2	20020801	WO 2002-US2004	20020125
	WO 2002058685	A3	20030501		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002183305	A1	20021205	US 2002-57646	20020125
PRAI	US 2001-264275P	P	20010126		
	US 2001-323842P	P	20010921		

OS MARPAT 137:119671
GI



I

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivs. thereof; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT **163222-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-

hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)
RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:487576 CAPLUS
DN 137:41758
TI Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents and in the treatment of atherosclerosis
IN Ghosal, Anima; Zbaida, Shmuel; Chowdhury, Swapan K.; Iannucci, Robert M.; Feng, Wenqing; Alton, Kevin B.; Patrick, James E.; Davis, Harry R.
PA Schering Corporation, USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002050090	A1	20020627	WO 2001-US49127	20011217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002031049 A5 20020701 AU 2002-31049 20011217

PRAI US 2000-256875P P 20001220

WO 2001-US49127 W 20011217

OS MARPAT 137:41758

AB Hypocholesterolemic sugar-substituted 2-azetidinone compds. are disclosed, as are a method of lowering cholesterol by administering these compds., pharmaceutical **compns**. contg. them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

IT **438576-93-3**

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)

RN 438576-93-3 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, labeled with carbon-14, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-33-1D**, glucuronides

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-33-1 190448-57-8**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sugar-substituted 2-azetidinones useful as hypocholesterolemics and in atherosclerosis treatment)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-

hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 190448-57-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:352625 CAPLUS
DN 129:41376
TI Preparation of sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
IN Yumibe, Nathan P.; Alton, Kevin B.; Van Heek, Margaret; Davis, Harry R.; Vaccaro, Wayne D.
PA Schering Corp., USA
SO U.S., 18 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5756470	A	19980526	US 1996-741179	19961029
	CN 1205707	A	19990120	CN 1996-199226	19961029
	CN 1103780	B	20030326		
PRAI	US 1996-741179	A	19961029		

OS MARPAT 129:41376
GI



I

AB Hypocholesterolemic sugar-substituted 2-azetidinones I (R = H, OH, sugar; R1 = alkylene, cycloalkylene, phenylene, alkenylene; G = sugar residue; Q = bond, spiro group; Ar, Ar1 = aryl), are disclosed, as well as a method of lowering cholesterol by administering said compds., pharmaceutical **compns**. contg. them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis. Thus, 1-O-[4-[trans-(3R,4S)-1-(4-fluorophenyl)-2-oxo-3-[3-[(S)-hydroxy-4-fluorophenylpropyl]]-4-azetidinyl]phenyl]-.beta.-D-glucuronic acid was prepd. as anticholesteremic agent 58 % redn. in plasma cholesterol with 3 mg/kg dose in hamsters.

IT **190448-57-8P 190448-58-9P 190448-60-3P**
190448-63-6P 190448-79-4P 208259-77-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sugar substituted azetidinones useful as hypocholesterolemic agents)

RN 190448-57-8 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190448-58-9 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-1-(4-iodophenyl)-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190448-60-3 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(.beta.-D-glucopyranosyloxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190448-63-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-2-azetidinyl]phenyl, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190448-79-4 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-hydroxy-3-(4-iodophenyl)propyl]-4-oxo-2-azetidinyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208259-77-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-[(3-O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-33-1P 190448-83-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sugar substituted azetidinones useful as hypocholesterolemic agents)
RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 190448-83-0 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, 4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-

3-hydroxy-3-(4-iodophenyl)propyl]-4-oxo-2-azetidinyl]phenyl, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis hist

(FILE 'HOME' ENTERED AT 10:50:17 ON 07 SEP 2003)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 07 SEP 2003
L1 STRUCTURE UPLOADED
L2 2 S L1 SSS SAM
L3 218 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:52:15 ON 07 SEP 2003
L4 16 S L3 AND COMPOSITION
L5 9 S L4 AND (ANTIDIABETIC OR HMG OR PPAR)

=> dis l5 1-9 bib abs hitstr

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:633275 CAPLUS
DN 139:169333
TI Novel anticholesterol **compositions** and method for using same
IN Dudley, Robert; Liao, Shutsung; Song, Ching
PA USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003153541	A1	20030814	US 2002-174934	20020619
WO 9922728	A1	19990514	WO 1998-US23041	19981030
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6576660	B1	20030610	US 2000-530443	20000428
US 2002107233	A1	20020808	US 2002-72128	20020208

	US 2002193357	A1	20021219	US 2002-137695	20020502
PRAI	US 1997-63770P	P	19971031		
	WO 1998-US23041	W	19981030		
	US 1999-131728P	P	19990430		
	US 2000-530443	A2	20000428		
	US 2000-560236	A2	20000428		
	US 2001-267493P	P	20010208		
	US 2001-288643P	P	20010503		
	US 2001-348020P	P	20011108		
	US 2002-72128	A2	20020208		
	US 2002-137695	A2	20020502		

AB Disclosed are **compns**., methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concn., for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The **compns**., methods, combinations, and kits of the present invention are pharmaceutical **compns**. comprising at least two of an LXR receptor modulator, a therapeutically effective amt. of a catechin, and/or a therapeutically effective amt. of a lipid regulating agent, such as a **HMG**-CoA reductase inhibitor, a fibric acid deriv., niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compd., and an unsatd. omega-3 fatty acid.

IT **163222-33-1**, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholesterol **compns**. contg. LXR modulators and lipid regulating agents)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:492702 CAPLUS

DN 139:47580

TI Combinations of hormone replacement therapy **composition**(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women

IN Strony, John T.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003119796	A1	20030626	US 2002-247085	20020919
	US 2003105028	A1	20030605	US 2002-166942	20020611

PRAI US 2001-324118P P 20010921
US 2002-166942 A2 20020611
US 2000-256875P P 20001220
US 2001-23295 A2 20011217
OS MARPAT 139:47580
AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one hormone replacement therapy **compn**.; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5.alpha.-stanols.
IT **163222-32-0P 163222-33-1P 163380-15-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of sterol absorption inhibitors for the combined use with hormone replacement therapy **compns**. and treatments for vascular conditions in post-menopausal women)
RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 163380-15-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:575765 CAPLUS
DN 137:140435
TI Benzopyrancarboxylic acid derivatives with **PPAR** agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical **compositions**, and use
IN Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
PA USA
SO U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002103242	A1	20020801	US 2001-21667	20011029
WO 2002060434	A2	20020808	WO 2001-US49501	20011026
WO 2002060434	A3	20030619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-244698P P 20001031
OS MARPAT 137:140435
GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (**PPAR**) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other **PPAR** alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH2, CO; R1 = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R1 forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO2, CH2, (un)substituted NH; n = 1-6; R4 = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their prepn. is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH2O(CH2)3Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alk. hydrolysis (100%), to give title compd. II. **PPAR** binding assays using human recombinant **PPAR** are described without data. Co-administration of compds. I with a variety of other drug categories, including a no. of specific drugs, is claimed.

IT **163222-33-1**, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic **compns**. also contg.; prepn. of benzopyrancarboxylic acid derivs. as **PPAR** agonists for treatment of diabetes and lipid disorders)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574958 CAPLUS
DN 137:135087
TI Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.
PA Schering Corporation, USA
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058734	A2	20020801	WO 2002-US2013	20020125
	WO 2002058734	A3	20030703		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002147184	A1	20021010	US 2002-56680	20020125
	US 2002192203	A1	20021219	US 2002-136968	20020501
PRAI	US 2001-264275P	P	20010126		
	US 2001-264396P	P	20010126		
	US 2001-264600P	P	20010126		
	US 2001-324123P	P	20010921		
	US 2001-323839P	P	20010921		
	US 2002-57323	A3	20020125		

OS MARPAT 137:135087
AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor administered in an amt. of 0.1-1000 mg/day; and (b) at least one blood modifier administered in an amt. of 1-1000 mg/day, which can be useful for treating vascular conditions, e.g., diabetes and obesity, and lowering plasma levels of sterols in mammals. A sterol absorption inhibitor is an azetidinone compd. or a .beta.-lactam, while a blood modifier was selected from anticoagulants, antithrombotics, fibrinogen receptor antagonists, platelet aggregation inhibitors, hemorheol. agents, lipoprotein assocd. coagulation inhibitors, Factor VIIa inhibitors, and Factor Xa inhibitors. Prepn. of a sterol inhibitor ezetimibe is described.
IT **163222-32-0P 163380-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders)
RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163380-15-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-33-1P**, Ezetimibe **163380-16-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of sterol absorption inhibitors with blood modifiers for treatment of vascular disorders)
RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 163380-16-3 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574957 CAPLUS
DN 137:135086
TI Combinations of bile acid sequestrant(s) and azetidinone sterol absorption inhibitor(s) and treatments for vascular indications
IN Davis, Harry R.; Kosoglou, Teddy
PA Schering Corporation, USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058733	A2	20020801	WO 2002-US2010	20020125
	WO 2002058733	C2	20021121		
	WO 2002058733	A3	20030626		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003053981	A1	20030320	US 2002-57534	20020125
PRAI	US 2001-264600P	P	20010126		
	US 2001-323842P	P	20010921		

OS MARPAT 137:135086
GI



I

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT **163222-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of bile acid sequestrant and azetidinone sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:574956 CAPLUS

DN 137:129904

TI Combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases

IN Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard

PA Schering Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002058732	A2	20020801	WO 2002-US2009	20020125
WO 2002058732	A3	20030703		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002151536	A1	20021017	US 2002-57323	20020125
US 2002192203	A1	20021219	US 2002-136968	20020501
PRAI US 2001-264396P	P	20010126		
US 2001-323839P	P	20010921		
US 2002-57323	A3	20020125		

OS MARPAT 137:129904

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (**PPAR**) activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone 4, croscarmellose sodium 8, sodium lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets contg. a **PPAR** activator such as ezetimibe. Synthetic prepn. of ezetimibe from fluorohenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of fenofibrate was well tolerated and caused a significant redn. in LDL-C as compared to either drug alone or placebo.

IT **163222-33-1**, Ezetimibe.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption inhibitors for treatment of vascular diseases)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574955 CAPLUS
DN 137:129903
TI Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
IN Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058731	A2	20020801	WO 2002-US1196	20020125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003069221	A1	20030410	US 2002-57339	20020125
	US 2002192203	A1	20021219	US 2002-136968	20020501
PRAI	US 2001-264275P	P	20010126		
	US 2001-264396P	P	20010126		
	US 2001-264600P	P	20010126		
	US 2001-323842P	P	20010921		
	US 2001-323839P	P	20010921		
	US 2002-57323	A3	20020125		

OS MARPAT 137:129903
GI



I

AB The present invention provides **compns**., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepd. contg. cardiovascular agents which can be coadministered with formulations contg., e.g., I. The prepn. of I was given.

IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-32-0 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163222-33-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574926 CAPLUS
DN 137:135094
TI The use of substituted azetidinone compounds for the treatment of sitosterolemia
IN Davis, Harry R.
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058696	A2	20020801	WO 2002-US1195	20020125
	WO 2002058696	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002169134	A1	20021114	US 2002-57629	20020125
PRAI	US 2001-264645P	P	20010126		

OS MARPAT 137:135094
GI



I

AB The invention discloses the use of sterol absorption-inhibiting compds., pharmaceutical **compns**. thereof, therapeutic combinations, and their use in combination with other lipid-lowering agents to treat or prevent sitosterolemia and/or to lower the concn. of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or

preventing vascular disease and coronary events also are provided. The methodol. and **compns**. of the invention use substituted azetidinone compds., e.g. I (prepn. described).

IT **163222-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(azetidinone derivs. for treatment of sitosterolemia)

RN 163222-33-1 CAPLUS

CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **444313-49-9 444313-50-2 444313-51-3**
444313-53-5 444313-55-7 444313-57-9
444313-59-1 444313-60-4 444313-61-5
444313-62-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(azetidinone derivs. for treatment of sitosterolemia)

RN 444313-49-9 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75330-75-5
CMF C24 H36 O5

Absolute stereochemistry.



RN 444313-50-2 CAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-.beta.,.delta.,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (.beta.R,.delta.R,1S,2S,6S,8S,8aR)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 81093-37-0
CMF C23 H36 O7

Absolute stereochemistry.



RN 444313-51-3 CAPLUS
CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-rel-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 93957-54-1
CMF C24 H26 F N O4

Relative stereochemistry.
Double bond geometry as shown.



RN 444313-53-5 CAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 79902-63-9
CMF C25 H38 O5

Absolute stereochemistry.



RN 444313-55-7 CAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (.beta.R,.delta.R)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 134523-00-5
CMF C33 H35 F N2 O5

Absolute stereochemistry.



RN 444313-57-9 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



RN 444313-59-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-, mixt. with (4R,6S)-6-[(1E)-2-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 141750-63-2
CMF C25 H22 F N O3

Absolute stereochemistry.
Double bond geometry as shown.



RN 444313-60-4 CAPLUS
CN Cholestyramine, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 11041-12-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 444313-61-5 CAPLUS
CN 1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 182815-44-7
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x . x Cl H

CM 3

CRN 182815-43-6
CMF (C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl)x
CCI PMS

CM 4

CRN 182815-42-5
CMF C12 H27 N2 . Cl



CM 5

CRN 92162-19-1
CMF C13 H27 N



CM 6

CRN 107-11-9
CMF C3 H7 N



CM 7

CRN 106-89-8
CMF C3 H5 Cl O



RN 444313-62-6 CAPLUS
CN Colestipol, mixt. with (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (9CI) (CA INDEX NAME)

CM 1

CRN 163222-33-1
CMF C24 H21 F2 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 50925-79-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **163222-32-0P 163380-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; azetidinone derivs. for treatment of sitosterolemia)

RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163380-15-2 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:574915 CAPLUS
DN 137:119671
TI Combinations of nicotinic acid and derivatives thereof and azetidine sterol absorption inhibitor(s) and treatments for vascular indications
IN Davis, Harry R.; Kosoglou, Teddy
PA Schering Corporation, USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058685	A2	20020801	WO 2002-US2004	20020125
	WO 2002058685	A3	20030501		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002183305	A1	20021205	US 2002-57646	20020125
PRAI	US 2001-264275P	P	20010126		
	US 2001-323842P	P	20010921		

OS MARPAT 137:119671
GI



I

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivs. thereof; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. The in vivo efficacy of I as a cholesterol absorption inhibitor was detd. in hamsters.

IT **163222-33-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)

RN 163222-33-1 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-

hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **163222-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combinations of nicotinic acid and derivs. and azetidine sterol absorption inhibitor(s) for treatment of vascular indications)
RN 163222-32-0 CAPLUS
CN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(phenylmethoxy)phenyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> dis hist

(FILE 'HOME' ENTERED AT 10:50:17 ON 07 SEP 2003)

FILE 'REGISTRY' ENTERED AT 10:50:27 ON 07 SEP 2003
L1 STRUCTURE UPLOADED
L2 2 S L1 SSS SAM
L3 218 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:52:15 ON 07 SEP 2003
L4 16 S L3 AND COMPOSITION
L5 9 S L4 AND (ANTIDIABETIC OR HMG OR PPAR)